Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

InspireMD's CGuard EPS shows sustained benefit in extension study; shares ahead 8% premarket

Published 05/30/2018, 08:10 AM
Updated 05/30/2018, 08:10 AM
© Reuters.  InspireMD's CGuard EPS shows sustained benefit in extension study; shares ahead 8% premarket
  • InspireMD (NYSEMKT:NSPR) is up 8% premarket on light volume in response to its announcement of positive results from a two-year follow-up period in patients with carotid artery stenosis (narrowing) at increased risk of stroke who received the CGuard EPS. The data were presented at EuroPCR in Paris.
  • The extension portion, a continuation of the PARADIGM study, showed no major strokes up to 30 days post-procedure (251 patients). There was one death, determined to be unrelated to the device. There were no strokes or stroke-related deaths between months 12 and 24.
  • The company says CGuard EPS is designed to prevent embolization by trapping potential emboli (e.g., blood clot, air bubble, fatty deposit) against the arterial wall by virtue of its MicroNet technology.
  • Now read: Oragenics' AG013 shows favorable safety profile in mid-stage OM study; shares up 34% premarket


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.